drugset / Trial / NCT05513586
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
NaSingle-groupOpen-labelTreatment
Summary
The main aim of the study is to check side effect from the study treatment with TAK-771 in long term. Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.
Timeline
- Start
- 2022-09-13
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Infusion | Unknown | 10 % | Subcutaneous |
| Background | rHuPH20 | Protein / enzyme biologic | 80 unknown | Subcutaneous |